Related Experiment Video
Updated: Jul 5, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
[Insulin therapy at the hospital setting]
J Sáez de la Fuente1, V Granja Berná, M A Valero Zanuy
1Servicio de Farmacia, Hospital Universitario 12 de Octubre, Madrid, Spain. javiersaezfuente@hotmail.com
Nutricion Hospitalaria
|May 2, 2008
Summary
Hospital hyperglycemia increases risks, but fear of hypoglycemia leads to poor insulin management. Individualized insulin therapy is crucial for better glycemic control and reduced patient complications.
Area of Science:
- Internal Medicine
- Endocrinology
- Pharmacology
Context:
- Hyperglycemia in hospitalized patients is linked to adverse outcomes, including infections and longer stays.
- Effective insulin therapy is vital for managing inpatient glycemic control.
- Current practices often involve suboptimal insulin dosing due to hypoglycemia concerns.
Purpose:
- To review key aspects of insulin use in the hospital setting.
- To analyze insulin types, efficacy factors, and administration routes.
- To discuss challenges and propose improvements in hospital insulin management.
Summary:
- This review examines insulin types, efficacy, and administration for hospitalized patients.
- It highlights how fear of hypoglycemia leads to inadequate insulin prescription and high glycemic targets.
- Individualized management is advocated to replace outdated regimens.
Impact:
- Optimizing insulin therapy can improve glycemic control in hospitalized patients.
- Reduced hyperglycemia is associated with fewer post-surgical infections and neurological complications.
- Implementing individualized strategies can lead to better patient outcomes and decreased healthcare costs.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...